# Study of PK/PD, Safety and Tolerability of LIK066 in Patients With Decreased Renal Function.

> **NCT03131479** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 53 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** LIK066

## Key facts

- **NCT ID:** NCT03131479
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-28
- **Primary completion:** 2018-01-16
- **Final completion:** 2018-01-16
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03131479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03131479, "Study of PK/PD, Safety and Tolerability of LIK066 in Patients With Decreased Renal Function.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03131479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*